Coronavirus company news summary – Sanofi steps up to support Janssen’s Covid-19 vaccine manufacturing – Novavax completes Covid-19 vaccine Phase III enrolment in US and Mexico

23 February 2021 (Last Updated February 23rd, 2021 09:23)

23 February 2021

Chinese Kintor Pharmaceutical has completed recruitment of 588 patients for its clinical trial of Proxalutamide in hospitalised Covid-19 patients in Brazil. Results of the interventional, placebo controlled, double-blinded, randomised, and multi-centre study are expected in March 2021.

India-based PNB Vesper Life Sciences announced positive results from its completed Phase II clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to fight Covid-19. The company further stated that it will soon apply for emergency use authorisation of the drug. PNB was authorised by the Drug Controller General in early September 2020 to conduct the Phase II clinical trial.

Novavax has completed the enrolment of PREVENT-19, its pivotal Phase III study in the US and Mexico. The trial will evaluate the safety, efficacy, and immunogenicity of the company’s Covid-19 vaccine candidate NVX-CoV2373. The company previously reported positive interim efficacy results of the recombinant protein-based vaccine in an ongoing Phase III clinical trial in the UK.

Sanofi has entered into an agreement with Janssen to support the manufacturing of the latter’s Covid-19 vaccine to meet the global supply requirements. This is Sanofi’s second commitment to leverage its manufacturing network to bolster global Covid-19 vaccine supply. Meanwhile, Janssen has applied for emergency use authorisation of its single-dose vaccine candidate to the US FDA, as well as for conditional marketing authorisation with the European Medicines Agency.